US 11,964,024 B2
B7H4-targeted antibody-drug conjugates and methods of use thereof
Timothy B. Lowinger, Carlisle, MA (US); Chen-Ni Chin, Somerville, MA (US); Marc I. Damelin, Needham, MA (US); and Dorin Toader, Cambridge, MA (US)
Assigned to Mersana Therapeutics, Inc., Cambridge, MA (US)
Filed by Mersana Therapeutics, Inc., Cambridge, MA (US)
Filed on Jan. 4, 2022, as Appl. No. 17/568,376.
Claims priority of provisional application 63/172,968, filed on Apr. 9, 2021.
Claims priority of provisional application 63/133,707, filed on Jan. 4, 2021.
Prior Publication US 2022/0233707 A1, Jul. 28, 2022
Int. Cl. A61K 47/68 (2017.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01)
CPC A61K 47/6803 (2017.08) [A61K 47/6857 (2017.08); A61K 47/6869 (2017.08); A61K 47/6883 (2017.08); A61P 35/00 (2018.01); C07K 16/3023 (2013.01); C07K 16/3069 (2013.01); C07K 16/32 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01)] 30 Claims
 
1. An isolated antibody that specifically binds B7-H4 comprising a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence GFIVSRNY (SEQ ID NO: 2), a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence IYGSGRT (SEQ ID NO: 3), a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence ARDADYGLDV (SEQ ID NO: 16) or the amino acid sequence ARDADYGMDV (SEQ ID NO: 10), a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence QSVSSSY (SEQ ID NO: 53), a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence GAS (SEQ ID NO: 54), and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence QQYGSSPLYT (SEQ ID NO: 55).